An observational study in Kidney Transplant Failure and Rejection and Pediatric Kidney Disease, sponsored by Radboud University Medical Center. Completed. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Radboud University Medical Center · Observational
Registry study in which data of all pediatric kidney recipients in the Netherlands (registered in the Nederlandse Orgaan Transplantatie Registry) are studied to develop a risk calculator for graft loss.
The pre-transplantation parameters of all recipients are used to do a multivariable regression analysis.
The B-coefficients of this analysis will be used to develop a risk calculator that predicts graft survival after transplantation per year of transplantation.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's enrollment of 1,425 is above the median of 192 across 1,033 observational studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
All pediatric kidney recipients that received their kidney \<18 years in the Netherlands
Pediatric kidney recipients
Exclusion Criteria:
None, observational
Graft survival
Functioning graft of death with functioning graft. Survival graph: Percentage recipients with a functioning graft over time
Time frame: Up to 50 years after transplantation
No study locations are listed for this record.
Plan to share: No — Not owner of the data, NOTR owns the data
No publications or documents are linked to this record.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Radboud University Medical Center